IOC Q4 Net Profit comes at Rs1,236 Cr
IOC
Q4 Net Profit comes at Rs1, 236 Cr
Total
Income at Rs.80, 449.7 Cr
EBITDA
at Rs.10, 044 Cr
EBITDA
Margin At 5%
GRM
At $3/bbl Vs $6/bbl (QoQ)
Canara Bank Q4: Net Loss at Rs3,905 Cr
Canara
Bank Q4: Net Loss at Rs3, 905 Cr
Gross
NPA At 9.4% Vs 5.84% (QoQ)
Gross
NPA +59.7% at Rs.31, 638 Cr Vs Rs.19, 813 Cr (QoQ)
Net
NPA At 6.42% Vs 3.90% (QoQ)
Tax
Write-back At Rs.779.5 Cr Vs Expense of Rs.110 Cr (YoY)
Provisions
at Rs.6, 331 Cr Vs Rs.1, 429 Cr (QoQ)
NII
-4.5% at Rs.2, 374 Cr Vs Rs.2, 486 Cr (YoY)
SBI Q4FY16: Mixed Bag performance, Asset quality worsens
State Bank of India Q4FY16 results first cut: Mixed Bag performance
SBI Q4: Net Profit -66.2% At Rs.1,264 Cr Vs Rs.3,742 Cr (YoY)
Gross NPA +34.9% At Rs.98,172 Cr Vs Rs.72,791 Cr (QoQ)
Gross NPA At 6.5% Vs 5.1% (QoQ)
Net NPA At 3.81% Vs 2.89% (QoQ)
Net NPA +38.7% At Rs.55,807 Cr Vs Rs.40,249 Cr (QoQ)
Slippages At Rs.30,312 Cr Vs Rs.20,692 Cr (QoQ)
Provisions For NPA At Rs.12,139.2 Cr Vs Rs.7,644.6 Cr (QoQ)
Lupin gains on receiving EIR for Mandideep facility
Shares of Lupin gained 3% to Rs1507 on NSE on back of reports that
the company has got Establishment Inspection Report (EIR) for its Mandideep
facility.
This is sentimentally positive for Lupin; stock is up by 3%; USFDA
clearance for Goa plant will be key to watch for going forward.
Torrent Pharma in talks to buy Glochem Industries for Rs300
crore
Torrent
Pharma in talks to buy Glochem Industries for Rs300 crore – Long term positive
for Torrent if deal goes thru
Torrent
Pharma is in advanced talks to buy bulk drugs supplier Glochem Industries for
about Rs300 crore.
Glochem
is a medium-sized company that makes bulk drugs, or active ingredients, which
are used as raw material for medicines and has USFDA approved sites in
Hyderabad and Vizag where oral bulk actives are manufactured.
Get real time advice for Intraday Trading Tips , Share Market Live , Intraday Equity Tips , Stock Trading tips , Free Intraday Tips , Best Accurate Stock Tips , NSE Stock market Tips and all Maket Updates .
0 comments:
Post a Comment